Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Sponsor: Genentech, Inc.
This PHASE1/PHASE2 trial investigates Prostate Cancer and is currently completed. Genentech, Inc. leads this study, which shows 35 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
35 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Sep 2022 — Oct 2023 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 30 earlier versions
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
Sep 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2018 — Apr 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Angers, France , Arezzo, Italy , Athens, Greece , Badalona, Spain , Baltimore, United States , Birmingham, United Kingdom , Brasov, Romania , Brno, Czechia , Bucharest, Romania and 41 more locations